Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceutical Chemicals

Gilead CEO Milligan to step down

by Lisa M. Jarvis
July 28, 2018 | A version of this story appeared in Volume 96, Issue 31

 

John F. Milligan will step down as head of Gilead Sciences at the end of the year. Milligan has spent his entire career at the Foster City, Calif.-based biotech firm, ascending to president in 2008 and CEO in 2016. He took over the top role at a time when Gilead was under pressure to make a splashy acquisition that could help offset an expected sales dive for its hepatitis C drug franchise; the company subsequently paid nearly $12 billion for CAR-T therapy-focused Kite Pharma. Milligan’s successor has yet to be named.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.